Tekla Life Sciences Investors Stock Forecast, Price & News

Wall Street analysts have given Tekla Life Sciences Investors a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tekla Life Sciences Investors wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Tekla Life Sciences Investors saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 48,300 shares, a drop of 60.5% from the March 31st total of 122,300 shares. Based on an average daily trading volume, of 86,900 shares, the short-interest ratio is currently 0.6 days.
View Tekla Life Sciences Investors' Short Interest.

Tekla Life Sciences Investors' stock was trading at $14.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HQL shares have increased by 32.7% and is now trading at $19.71.
View which stocks have been most impacted by COVID-19.

Tekla Life Sciences Investors declared a quarterly dividend on Wednesday, February 17th. Shareholders of record on Friday, February 26th will be paid a dividend of $0.43 per share on Wednesday, March 31st. This represents a $1.72 annualized dividend and a yield of 8.73%. The ex-dividend date of this dividend is Thursday, February 25th. This is an increase from Tekla Life Sciences Investors's previous quarterly dividend of $0.40.
View Tekla Life Sciences Investors' dividend history.

Tekla Life Sciences Investors pays an annual dividend of $1.58 per share and currently has a dividend yield of 8.14%. HQL has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
View Tekla Life Sciences Investors' dividend history.

Some companies that are related to Tekla Life Sciences Investors include The Gabelli Equity Trust (GAB), Royce Value Trust (RVT), Tri-Continental (TY), Liberty All-Star Equity Fund (USA), iShares MSCI Australia ETF (EWA), Tortoise Energy Infrastructure (TYG), Boulder Growth & Income Fund (BIF), iShares MSCI Hong Kong ETF (EWH), Nuveen Nasdaq 100 Dynamic Overwrite Fund (QQQX), Aberdeen Asia-Pacific Income Fund (FAX), Central Securities (CET), Tekla Healthcare Investors (HQH), General American Investors (GAM), AllianceBernstein Global High Income Fund (AWF) and SPDR Bloomberg Barclays International Treasury Bond ETF (BWX).
View all of HQL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tekla Life Sciences Investors investors own include NVIDIA (NVDA), Energy Transfer (ET), QUALCOMM (QCOM), AT&T (T), Enbridge (ENB), International Business Machines (IBM), Kinder Morgan (KMI), Main Street Capital (MAIN), Pfizer (PFE) and Weyerhaeuser (WY).

Tekla Life Sciences Investors trades on the New York Stock Exchange (NYSE) under the ticker symbol "HQL."

Tekla Life Sciences Investors' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Advisors Asset Management Inc. (1.72%), Flagship Harbor Advisors LLC (1.33%), Cohen & Steers Inc. (0.68%), UBS Group AG (0.50%), Atlantic Union Bankshares Corp (0.41%) and Ameriprise Financial Inc. (0.38%).
View institutional ownership trends for Tekla Life Sciences Investors.

HQL stock was sold by a variety of institutional investors in the last quarter, including Cohen & Steers Inc., Usca Ria LLC, Stifel Financial Corp, Titus Wealth Management, Shepherd Kaplan Krochuk LLC, Guggenheim Capital LLC, Powell Investment Advisors LLC, and Eudaimonia Partners LLC.
View insider buying and selling activity for Tekla Life Sciences Investors or view top insider-selling stocks.

HQL stock was purchased by a variety of institutional investors in the last quarter, including Atlantic Union Bankshares Corp, Advisors Asset Management Inc., Hennion & Walsh Asset Management Inc., Flagship Harbor Advisors LLC, UBS Group AG, International Assets Investment Management LLC, Quad Cities Investment Group LLC, and Commonwealth Equity Services LLC.
View insider buying and selling activity for Tekla Life Sciences Investors or or view top insider-buying stocks.

Shares of HQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HQL stock can currently be purchased for approximately $19.71.

Tekla Life Sciences Investors has a market capitalization of $478.54 million.

The official website for Tekla Life Sciences Investors is www.teklacap.com.

Tekla Life Sciences Investors is headquartered at 2 LIBERTY SQUARE 9TH FLOOR, BOSTON MA, 02109.

Tekla Life Sciences Investors' mailing address is 2 LIBERTY SQUARE 9TH FLOOR, BOSTON MA, 02109. The company can be reached via phone at 617-772-8500 or via email at [email protected]